Entellus Medical, Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 6,028 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $19.17, for a total value of $115,556.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Brian E. Farley also recently made the following trade(s):

  • On Monday, October 2nd, Brian E. Farley sold 3,972 shares of Entellus Medical stock. The stock was sold at an average price of $19.10, for a total value of $75,865.20.

Shares of Entellus Medical, Inc. (ENTL) traded up 2.82% during mid-day trading on Wednesday, hitting $20.05. The company had a trading volume of 219,809 shares. The firm’s 50 day moving average is $17.67 and its 200-day moving average is $17.67. Entellus Medical, Inc. has a 12-month low of $12.31 and a 12-month high of $22.57. The firm’s market cap is $508.69 million.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The company had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) earnings per share. On average, equities analysts expect that Entellus Medical, Inc. will post ($1.61) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/entellus-medical-inc-entl-director-brian-e-farley-sells-6028-shares.html.

Several analysts recently issued reports on ENTL shares. Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. BidaskClub raised Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Finally, Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $21.83.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Kopp Investment Advisors LLC boosted its holdings in Entellus Medical by 0.5% during the second quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after purchasing an additional 55 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Entellus Medical by 5.6% during the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 573 shares in the last quarter. First Mercantile Trust Co. boosted its holdings in Entellus Medical by 45.3% during the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after purchasing an additional 2,557 shares in the last quarter. Bank of America Corp DE boosted its holdings in Entellus Medical by 53.8% during the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after purchasing an additional 2,594 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its holdings in Entellus Medical by 61.7% during the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 2,635 shares in the last quarter. 70.24% of the stock is currently owned by institutional investors.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.